Cytokinetics, Inc. sells a drug, Myqorzo®, indicated for the treatment of obstructive hypertrophic cardiomyopathy (oHCM).  The drug’s active ingredient is aficamten, which is a cardiac myosin inhibitor.  In 2020, Bristol-Myers Squibb acquired a company that sells one of the only other competing drugs to Myqorzo.  Then in May 2026, BMS acquired a patent covering the use of aficamten to treat cardiac hypercontractility.  Cytokinetics claims BMS acquired this patent only to stifle Myqorzo’s commercial potential.  On August 12, Cyotkinetics filed suit against BMS seeking a judgmentthat it does not infringe BMS’s aficamten patent.  Can Cytokinetics extinguish BMS’s patent threat against Myqorzo?